Sun Yat-sen University: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 16 Squamous Cell Carcinoma of Head and Neck studies with Sun Yat-sen University as lead sponsor. 13 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 10Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07766889Phase 2
• BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy ProgressionEnrolling by invitationNCT07618624Phase 2
• Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II StudyNot yet recruitingNCT07589049Phase 2
• Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Phase 1
• Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III TrialNot yet recruitingNCT07371897Phase 3
• A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07354984Phase 2
• Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal CancerNot yet recruitingNCT06861712Phase 2
• SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and HypopharynxRecruitingNCT06611137Phase 2
• 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell CarcinomaRecruitingNCT06492460Phase 3
• Myeloprotection With Trilaciclib in Pan-cancer PopulationNot yet recruitingNCT06297811Phase 2
• Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)RecruitingNCT05044117Phase 3
• Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCCRecruitingNCT04826679Phase 2
• Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And NeckRecruitingNCT03830385Phase 2
• Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06673693Phase 2
• Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06630780Not applicable
• Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell CarcinomaStatus unknownNCT01334320Not applicable